EMA committee recommends Rasonque for previously treated metastatic pancreatic cancer
October 19, 2026
AI summary — for doctors, generated from the source snippet
Why it matters
The committee recommended Revolution Medicines' RAS inhibitor Rasonque for adults whose pancreatic cancer had spread and progressed after at least one prior treatment. In a late-stage study of 500 patients, median survival was 12.4 months versus 6.7 months with chemotherapy.
Clinical relevance
Relevant to oncologists treating second-line pancreatic cancer, where the drug is already approved in the US.
Who should care
This is an AI-generated summary of the source's own press release/snippet, not a clinical recommendation. Verify against the original source before acting on it.
Original source summary
Bengaluru : A European Medicines Agency committee on Thursday recommended approval of Revolution Medicines' Rasonque in the EU for adults with pancreatic cancer that has spread and worsened after at least one prior treatment. Rasonque was approved in the US in August using an expedited review process. The drug works by blocking RAS proteins, which can drive cancer-cell growth. The drug was tested in a late-stage study of 500 patients, most with a RAS G12 mutation, whose cancer had progressed after earlier treatment. Patients receiving Rasonque lived for a median of 12.4 months, compared with 6.7 months for those receiving chemotherapy. Revolution Medicines did not immediately respond to Reuters request for comment. Also Read: USFDA Approves Revolution Medicines' Rasonque for Advanced Pancreatic Cancer After Survival Breakthrough
Verbatim from Medical Dialogues's own feed — "EU Medicines Agency Recommends Revolution Medicines' Rasonque for Advanced Pancreatic Cancer"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news